抗磷脂抗体与危重症 COVID-19 患者的血栓并发症有关吗？
Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?
机构信息
Laboratory of Hematology, Lariboisière Hospital, Paris University, Paris, France; INSERM UMRS 1140, Paris University, Paris, France.
Department of Medical and Toxicological Critical Care, Lariboisière Hospital, Paris University, Paris, France; INSERM UMRS 1144, Paris University, Paris, France.
出版信息
Thromb Res. 2020 Nov;195:74-76. doi: 10.1016/j.thromres.2020.07.016. Epub 2020 Jul 8.
• The prevalence of aPL antibodies is poorly documented in ICU COVID-19 patients. • LA based on dRVVT system was positive in 85% of critically ill COVID-19 patients. • LA was not associated with thrombotic complications. • The prevalence of elevated anticardiolipin IgG/M/anti-beta2-GPI IgG was of 12%.
• ICU 中 COVID-19 患者的 aPL 抗体流行情况记录不佳。
• 基于 dRVVT 系统的 LA 在 85%的危重症 COVID-19 患者中呈阳性。
• LA 与血栓并发症无关。
• 升高的抗心磷脂 IgG/M/抗β2-GPI IgG 的患病率为 12%。
Zotero 插件